Novartis Korea has surpassed ₩500 billion in annual sales for the first time since entering Korea. Despite the confusion of COVID-19, representative medicines and new products generated synergy, which led to the highest sales ever.

According to the Financial Supervisory Service on the 15th, Novartis Korea last year recorded ₩532 billion. With a 7.8% increase in sales compared to the previous year, it achieved the most sales among multinational pharmaceutical companies that entered Korea for the second consecutive year following 2019. This is the first time Novartis Korea has exceeded the annual sales of ₩500 billion since the inauguration of Novartis Korea in 1997. Operating profit was a